Lupin has launched Tiotropium Bromide Inhalation Powder, 18 mcg/capsule, for the treatment of chronic obstructive pulmonary disease (COPD) in the United States. Tiotropium Bromide Inhalation Powder, 18 mcg/capsule is a generic equivalent of Spiriva HandiHaler (Tiotropium Bromide Inhalation Powder), 18 mcg/capsule of Boehringer Ingelheim Pharmaceuticals, Inc.
With this launch, Lupin introduces an alternative to combat COPD, a condition impacting over 15 million adults in the US and ranked as the fourth leading cause of death in the country. By extending enhanced accessibility to cutting-edge products, Lupin actively contributes to alleviating the burden of COPD for patients across the nation.
Tiotropium Bromide Inhalation Powder (Reference Product Spiriva HandiHaler) had estimated annual sales of $1,264 million in the US (IQVIA MAT Mar 2023).
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
